Skip to Content
Merck
All Photos(1)

Documents

SML1691

Sigma-Aldrich

ZM323881 hydrochloride

≥98% (HPLC)

Synonym(s):

5-((7-Benzyloxyquinazolin-4-yl)amino)-4-fluoro-2-methylphenol hydrochloride, ZM-323881 hydrochloride

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C22H18FN3O2 · HCl
CAS Number:
193000-39-4
Molecular Weight:
411.86
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

100

Assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 10 mg/mL, clear

storage temp.

2-8°C

InChI

1S/C22H18FN3O2.ClH/c1-14-9-18(23)20(11-21(14)27)26-22-17-8-7-16(10-19(17)24-13-25-22)28-12-15-5-3-2-4-6-15;/h2-11,13,27H,12H2,1H3,(H,24,25,26);1H

InChI key

AVRHWGLIYGJSOD-UHFFFAOYSA-N

Biochem/physiol Actions

ZM323881 is a selective inhibitor of VEGFR-2 with an IC50 value of 2 nM. ZM323881 is selective for VEGFR-2 over VEGFR-1 and other receptor tyrosine kinases including PDGFRβ, FGFR1, EGFR and erbB2. ZM323881 inhibited VEGF-A-induced endothelial cell proliferation with an IC50 value of 8 nM.
ZM323881 is also known as (5‐{[7‐(benzyloxy) quinazolin‐4‐yl]amino}‐4‐fluoro‐2‐methylphenol). It is capable of blocking the efflux function and altering breast cancer resistant protein (BCRP)-related multidrug resistance (MDR).

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302

Precautionary Statements

P264 - P270 - P301 + P312 - P501

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

C E Whittles et al.
Microcirculation (New York, N.Y. : 1994), 9(6), 513-522 (2002-12-17)
Vascular endothelial growth factor (VEGF) increases vascular permeability and angiogenesis in many pathological conditions including cancer, arthritis, and diabetes. VEGF activates VEGF-Receptor 1(VEGF-R1) and VEGF-Receptor 2 (VEGF-R2), which autophosphorylate to initiate a signaling cascade resulting in angiogenesis and increased microvascular
Selective reversal of BCRP-mediated MDR by VEGFR-2 inhibitor ZM323881
Zhang Yun-Kai, et al.
Biochemical Pharmacology, 132, 29-37 (2017)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service